Treatment monitoring of patients with epithelial ovarian cancer using invasive circulating tumor cells (iCTCs).

ABSTRACT:

Goals

Contemporary management of epithelial ovarian cancer (EOC) uses biomarkers to monitor response to therapy. This study evaluates the role of invasive circulating tumor cells (iCTCs) in monitoring EOC treatment in comparison with serum cancer antigen 125 (CA125).

Methods

Molecular and microscopic analyses were used to identify seprase and CD44 as tumor progenitor (TP) markers. The iCTC flow cytometry assay was optimized using blood donated by 64 healthy donors, 49 patients with benign abdominal diseases and 123 EOC patients. Serial changes in iCTCs and CA125 were measured in 129 blood and 169 serum samples, respectively, from 31 EOC patients to assess their concordance during therapy and their relationship with risk of progressive disease (PD).

Results

The assay h

SUBMITTER: Pearl ML 

PROVIDER: S-EPMC5568621 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature